Recent News

• 09.10.2025 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 09.06.2025 - Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
• 09.03.2025 - BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
• 09.02.2025 - BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
• 08.30.2025 - Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
• 08.27.2025 - BridgeBio to Participate in September Investor Conferences
• 08.25.2025 - BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Recent Filings

• 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.05.2025 - 144 Report of proposed sale of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.21.2025 - 144 Report of proposed sale of securities
• 08.20.2025 - 144 Report of proposed sale of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.19.2025 - 4 Statement of changes in beneficial ownership of securities